Questions discussed in this category
What factors (i.e. timing from transplant, dose, prior therapy) impact your decision?
Do the results change your clinical practice?
Frailty Index per Palumbo et al. PMID 25628469Is it practical to apply in clinics? Have you made decision changes based on it?
CAR-T (any specific preference of product?) vs bispecific antibodies vs any other specific agents not previously utilized?
13302108851310411769121781155710347105941044010202
Papers discussed in this category
Am J Transplant, 2016 Jun 09
Transplantation, 2021 Apr 27
Surgery, 2017 Jun 16
JAMA Oncol, 2020 Apr 16
Eur J Nucl Med Mol Imaging, 2018 Sep 28
Br J Radiol, 2018 Mar 20
Eur J Nucl Med Mol Imaging, 2013 Sep 13
BMC Cancer, 2019 Aug 08
Scand J Gastroenterol, 2021 Jan 20
Int J Endocrinol, 2021 Jan 23
Cancer Treat Rev, 2020 Dec 22
The New England journal of medicine, 2012-05-10
Nature communications, 2019-04-23
Blood, 2012 Aug 13
J Clin Oncol, 2020 Apr 16
Blood,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-10-10
The New England journal of medicine, 2017-04-06
The Lancet. Oncology, 2019-01
Blood,
Lancet, 2019 Jun 03
Blood,
Blood, 2015-03-26
Clin Lymphoma Myeloma Leuk, 2019 Oct 09
JCO Oncol Pract, 2019 Nov 25
The New England journal of medicine, 2019-05-30
N Engl J Med, 2022 Jun 05